Summary. The effect of interference with diacylglycerol metabolism was investigated in pancreatic mouse islets. In the presence of the diacylglycerol lipase inhibitor RHC 80267, glucose-induced insulin secretion was reduced 50-60%; whereas carbacholin-induced insulin secretion was unaffected. Addition of the diacylglycerol kinase inhibitor R 59 022 did not change glucose-stimulated insulin secretion but abolished the inhibition seen in the presence of RHC 80267. RHC 80267 increased islet glucose utilisation, measured as formation of tritiated water from 5-[3H]-glucose, 3-fold but did not affect glucose oxidation to CO2, lactate production or islet ATP levels. Glucose utilisation in leucocytes and hepatocytes was not increased by addition of RHC80267.
The participation of phospholipase C catalysed hydrolysis of phosphatidylinositoldiphosphate (PIP2) in regulation of insulin secretion has been substantiated during the past few years. Thus, one of the products of the reaction, inositol-l,4,5-trisphosphate has been shown to mobilise Ca 2+ from an endoplasmic reticulure pool of calcium [1, 2] , thereby leading to an increased conc of Ca 2+ in the cytosol. The other product in the phospholipase C reaction, diacylglycerol, is known to stimulate protein kinase C, which has also been suggested to be involved in regulation of insulin secretion [3] [4] [5] . Furthermore, diacylglycerol may be hydrolysed by diacylglycerol lipase and, in this way, lead to an increased production of arachidonic acid [6] which, by some authors, have been suggested to be a coupling factor in stimulus-secretion coupling in pancreatic islets [7, 8] .
In an attempt to further elucidate the importance of diacylglycerol for regulation of insulin secretion, we have investigated the effect of the diacylglycerol lipase inhibitor, RHC 80 267, [9] on insulin secretion and pancreatic islet metabolism. (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) Ci/mmol), 3H20 (5 mCi/mmol) and 1-acyl-2-[14C]-oleyl-glycerophosphocholine (50 mCi/mmol) were from Amersham Int. Buckinghamshire UK. Firefly lanterns used for preparation of luciferase was from Sigma Chemical Co, St. Louis, Mo, USA. RHC 80 267 was synthesised by Dr. P.Jacobsen, Institute of Medical Chemistry, University of Copenhagen, Denmark. R 59 022 was from Janssen Life Science Products, Beerse Belgium. Insulin standards, antibodies and 125I-insulin were given by Nordic Gentofte, Gentofte Denmark. Enzymes, including phospholipase C from Bacillus cereus, and coenzymes were from Boehringer, Mannheim, FRG. All other reagents were of analytical grade.
Preparation of tissue
Pancreatic islets were prepared by collagenase treatment of pancreata from male albino mice, weighing about 28 g each. The mice were fed ad libitum on a standard laboratory diet. Leucocytes were prepared by mixing 4 ml of human venous blood with 1 ml of 5% dextran solution and 10 ~tl of heparin (5000 U/ml). The mixture was allowed to sediment for 45 min at 37 ~ C. Plasma with leucocytes and a few erythrocytes was aspirated cautiously and centrifuged for 10 rain at low speed (150 x g). The pellet was resuspended and washed 3 times with Krebs-Henseleit buffer containing 16.7 mmol/1 glucose and 1% gelatin, 0.2% sodium acetate and 1 mg ascorbic acid/100 ml. Finally, the pellet was suspended in 2 ml of the same buffer, giving a concentration of 4-5000 leucocytes/~d.
Hepatocytes from rats were prepared by the collagenase method described by Dich et al. [10] . The hepatocytes were suspended in Ka'ebs-Henseleit buffer to a concentration of 2000 cells/~tl.
Glucose utilisation
Glucose ufilisation was measured as formation of tritiated water from 5-[3H]-glucose [11] . Ten islets or 6 ~tl of hepatocyte-or leucocyte-suspension were used in each batch. RHC 80267 was dissolved in dimethylsulfoxide (DMSO). Batches without islets and islet batches with glucose plus the solvent DMSO were run as control.
Glucose oxidation
Glucose oxidation was estimated as formation of 14C02 from U-[14C] -glucose. 14CO2 was measured as described by Thams et al. [5] . RHC 80267 was dissolved in DMSO giving a final concentration of 0.05% DMSO in the assay. K. Capito et al.: RHC 80 267 and pancreatic mouse islet metabolism anol: concentration HCI (1 : 2: 0.035, v/v). After further addition of 250 ]xl chloroform and 250 l-tl 0.9% NaC1, phase separation was achieved by centrifugation. Released ~4C-phosphoinositol was quantified by determination of radioactivity in the aqueous phase. The watersoluble product was identified by chromatography on Dowex-1 (formate) as being a mixture of inositol-l-monophosphate and 1,2-cyclic inositolmonophosphate. Measured under these conditions, the activity of PI-specific phospholipase C in fresh islet homogenate was 1.76 _+ 0.22 pmol. min. islet (n = 12). "]?he aqueous phase did not contain 14C-inositol. The enzyme also ])ydrolyses phosphatidylinositol 4,5-diphosphate.
Glycogen synthesis

Other enzyme assays
Adenylate cyclase was measured as described by Thams et al. [13] . Phospholipase A2 activity was measured as formation of [14C]-oleate from 1-oleyl-2-[~4C]-oleyl-glycerophosphocholine. The substrate was suspended in Hepes-buffer (50mmol/1; pH7.0), containing 2 mmol/1 CaC12 and incubated with islet homogenate for 2 h at 37 ~ C. The reaction was stopped, and the liberated oleic acid measured as described above for the diacylglycerol lipase assay.
Diacylglycerol lipase
For the assay of diacylglycerol lipase l-acyl-2-[14C]-oleyl-glycerol was prepared from 1-oleyl-2-[14C]-oleyl-glycerophosphocholine: 1-oleyl-2-[~4C]-oleyl-glycerophosphocholine was incubated for 2 h at 37~ in 200 gl of 50 mmol/1 Tris, HC1 pH 7.4 containing 5 mmol/1 CaC12, 5 mmol/1 MgC12 and 2.5 ~tg/ml of phospholipase C from Bacillus cereus. After incubation, the lipids were extracted 4 times with 1.5 ml of diethylether. The solvent was removed under nitrogen, and the radiolabelled lipids redissolved in petroleum ether and stored at -20 ~ C. In preliminary experiments, the formed [14C]-diacylglycerol was purified by thinlayer chromatography in isopropylether: acetic acid 96:4; but since the phospholipase C mediated hydrolysis went to completion, and the only radiolabelled product formed was 1,2-diacylglycerol, this purification was found to be unnecessary in further experiments.
The activity of diacylglycerol lipase was measured essentially as described by Rittenhouse-Simmons [12] . An aliquot of the radiolabelled diolein was evaporated under nitrogen and suspended with the help of a microprobe sonifier in 50 mmol/1 Hepes buffer pH 7.0 containing 100 mmol/l NaC1 and 0.005% Triton X-100. Three-five ~tg of islet homogenate protein was added to the suspension (final concentrations of diacylglycerol approx. 2 lxmol/1) in a total volume of 30 ~tl and incubated for 30 rain at 37~ RHC 80267 and indomethacin in the appropriate concns were added as DMSO solutions. The reaction was terminated by the addition of 1.5 ml of CHC13 :methanol: hexane (25:28:20, v/v). Then 0.5 ml of 50 mmol/1 boric acid and 50 mmol/1 K2CO3, pH 10 was added, and the radioactivity in the upper phase ([14C]-oleate) was counted.
The enzyme activity was linear with time for at least 1 h and with the amount of islet homogenate protein untill at least 8 lxg. Since the radioactive label was in the 2-position, the assay co-measures the activity of monoacylglycerol lipase, but since it was not possible to detect accumulation of monoacylglycerol, the two enzymes must work at least at the same rate.
PI-sepcific phospholipase C
Enzyme activity was measured in 235 ~tl of 50 retool/1 Tris buffer pH 7.4 containing 1 mmol/1 Ca 2+, 2 mmol/1 Li + and 0.2% human serum albumin. The final reaction mixture included 6-7 p~g of sonieated islet protein and 40 ~tmol/1 radiolabelled phosphatidylinositol added as a liposomal suspension prepared by brief sonication in 50 mmol/1 Tris buffer pH 7.4. The reaction was performed at 37 ~ for 15 min and terminated by addition of 500 p3 chloroform:meth-
A TP-determination
For measurement of ATP, batches of 15 islets were incubated for 45 min at 37~ in 40 lxl of Krebs buffer containing 16.7 mmol/1 glucose and 70 ~tmol/1 RHC 80267 or 0.1% DMSO. The incubation was terminated by addition of 20 ~tl of ice-cold I tool/1 perchloric acid, and ATP determined by the luciferase method described in [11] , except that 250 ~tl of 0.2 mol/1 Tris, acetate buffer pH 7.75, containing 2 mmol/1 MgSO4 and 1 mmol/1 EDTA was used as assay buffer.
Lactate production
Twenty islets were incubated for 2 h at 37~ in 50 txl of Krebs buffer containing glucose (3.3 or 16.7 mmol/1). Metabolism was arrested by addition of 70 ~tl of 50 retool/1 HC1. The tubes were heated at 60~ for 30 min to destroy endogenous NADH. After cooling and centrifugation, 2 x 50 lxl of the supernatant were transferred to cuvettes containing 1.2 ml of 0.4 tool/1 glycin buffer pH 9.5 with 0.16 mot/1 hydrazin, 2 retool/1 EDTA, 0.01 mmol/1 NAD + and 3.6 U of lactate dehydrogenase. After incubation at room temperature for 30 min, the fluorescence of the formed NADH was measured at a Ferrand fluorimeter. Blanks and standards were taken through the whole procedure.
Lipid synthesis
Sixty islets were incubated at 37 ~ C for 2 h in 60 gl of Krebs buffer containing 16.7 mmol/1 U-[14C]-glucose (spec. activity 3 mCi/mmol). After incubation, the medium was removed and the islets were washed once with Krebs buffer. 100 txl of 1 tool/1 citrate buffer, pH 3.0 and 1.8ml of CHC13:methanol (1:2) were added and the tubes were shaken for 30 rain. Then, 1.5 ml of CHC13 and 1.5 ml of 2 tool/1 KC1 were added followed by another 30 min of extraction of lipids. After extraction, the radioactivity in the chloroform phase was measured.
Determination of radiolabelled glycerol and anionic metabolites
Batches of 15 islets were incubated in 20 f.tl of Krebs buffer containing 0.83 ~tCi of U-[14C]-glucose at a concentration of 3.3 or 16.7 mmol/1 glucose and in the absence or presence of 70 Ixmol/1 RHC 80267 or 0.05% DMSO. Parallel controls were run without islets. The incuba-tion was carried out for 2 h at 37~ and stopped by the addition of 10 p,1 of 4% Triton X-100. After 10 rain at room temperature, the samples were immersed briefly in a boiling water bath and cooled on ice. Glycerol in the samples was phosphorylated by adding 20 p,1 of 0.3 mol/1 Tris-buffer pH 7.5, containing 5 mmol/1 ATP, 0.1 mol/1 MgSO4 and 4.3 U/ml of glycerokinase and incubating for 30 min at 37~ After completion of the phosphorylation reaction, aliquots of 40 p,1 were spotted on Whatman DE 81 anion exchange paper. The disks were dried and cautiously rinsed with a slow stream of water for about 10 min. After drying, the disks were transferred to 10 ml of instagel II, thus measuring the radioactivity in glycerol and anionic metabolites.
Insulin secretion
Insulin secretion experiments were done as batch type incubations [14] and the secreted insulin measured in a radioimmunoassay.
Statistical analysis
Statistical evaluation of the data was made by use of Students t-test
Results
Diacylglycerol lipase activity
The activity of diacylglycerol lipase in a homogenate of pancreatic islets was found to be 89 _+ 10 pmol. min. mg protein -~ (mean+SEM; n=3). RHC 80267 at a conc of 35 p~mol/l inhibited the enzyme activity 90+2% (mean_ SEM, n= 4). From dose-response studies (n=4), it was calculated that a 50% inhibition of the enzyme activity was obtained at 6 lxmol/1 RHC 80 267. This is similar to the effects described by Sutherland and Amin in canine platelets [9] . Indomethacin at a concentration of 140 lxmol/1, which in some tissues inhibits diacylglycerol lipase [12] , did not affect the activity of diacylglycerol lipase in islets. Ca 2+, which in some tissues activate diacylglycerol lipase [15] , did not affect the islet enzyme activity in a concentration of i mmol/1.
Insulin secretion
Dose-response studies of the effect of 17.5-70 ~tmol/1 RHC 80267 on insulin secretion was measured at 3 different glucose concentrations and in the presence of 5 mmol/1 glucose plus 100 p~mol/1 carbacholine (Table 1) .
Thirty-five txmol/1 RHC 80 267 inhibited insulin secretion induced by 10 or 17 mmol/1 glucose 45%, and addition of 70 ~tmol/1 RHC 80 267 at these glucose concentrations reduced the insulin secretory rate to basal values. The basal secretory rate was unaffected by addition of RHC 80 267 (results not shown). Insulin secretion potentiated by carbacholine was also unaffected by addition of RHC 80 267. In another series of experiments, the effect of a combined addition of RHC 80 267 and the diacylglycerol kinase inhibitor R 59 022 was investigated (Table 2) . In this case, no significant effect of either R 59022 or R 59 022 plus RHC 80 267 could be demonstrated.
Glucose utilisation
Glucose utilisation was measured as formation of tritiated water from 5-[3H]-glucose during a 2 h incubation of pancreatic islets. In the presence of 16.7 mmol/1 glucose RHC 80267 stimulated the glucose utilisation in a dose-dependent manner, reaching a 5-fold stimulation relative to the DMSO-control at 140 lxmol/1 RHC 80267 (Table 3) . At 3 and 10 mmol/l glucose a similar activation was seen (results not shown).
It is noteworthy that DMSO, which is used as a solvent for RHC 80 267, exhibits in itself an inhibitory effect on glucose utilisation. At a DMSO-concentration of 0.5% the inhibition was about 50% (not shown). This is remarkable as DMSO is usually considered relatively harmless and biologically indifferent. The inhibitory effect of DMSO was not seen in experiments with hepatocytes and leucocytes. 
Glucose oxidation and lactate production
During metabolism of 5-[3Ha-glucose, tritiated water is formed in the pentose cycle, in the triosephosphate isomerase reaction and in the enolase reaction, thus giving a measurement of glucose metabolism via glycolysis plus pentose cycle, as well as glycerolipid formation from glucose. In pancreatic islets, pentose cycle activity contributes approximately 3% [16] and glycerolipid production 3-6% [17] to the total glucose utilisation measured during incubation with a6.7 mmol/1 glucose.
To evaluate the effect of RHC 80267 on total glucose oxidation and on glycolysis, the possible effect of the diacylglycerol lipase inhibitor on 14CO2-production from U-[~4C]-glucose and lactate production was investigated ( Table 4) . As expected, glucose (a6.7 mmol/1) significantly (p < 0.001 and 0.05 respectively) accelerated the glucose oxidation and lactate production. Surprisingly, addition of RHC 80 267 or the solvent alone did not affect these parameters.
Conversion of glucose to glycerol, anionic metabolites and lipids
The stimulating effect of RHC 80267 is probably rather specific for pancreatic islets, since in 3 experiments with hepatocytes (glucose concentration= 16.7 mmol/1, conc of RHC 80267=70 ~tmol/l, and DMSO concentration=0.02%) the glucose utilisation was 82 + 9% (mean +_ SEM) of control values. Under the same conditions, the stimulation of islet glucose utilisation was 286 +24% of the control. In 4 experiments with leucocytes under the same assay conditions, glucose utilisation was 76 ___ 2% of the control.
As an uncoupling effect of RHC 80 267 on the oxidative phosphorylation in the islets might explain the increased glucose utilisation, a few experiments with 50 ~tmol/1 dinitrophenol in the presence of 16.7 mmol/1 glucose were performed in pancreatic islets. No significant stimulation of glucose utilisation was observed (results not shown). Measurements of islet ATP-content after incubation with a6.7mmol/1 glucose +_ RHC 80267 also indicated that RHC 80267 does not act as an uncloupling agent. Thus, the ATP content amounted to 4.9 _+ 0.7 pmol/islet in the absence and 5.6+0.8 pmol/islet in the presence of RHC 80267 (mean+ SEM, n = 9). The DMSO solvent did not affect the islet ATP content significantly.
Indomethacin (47 p~mol/1) in the presence of 10 mmol/1 glucose and 0.02% DMSO in 2 experiments increased glucose utilisation to 174 and 159% of the control, respectively. In the presence of a6.7 mmol/1
The possible effect of RHC 80 267 on metabolism of glucose through the lipogenetic pathway was estimated by measuring the production of radioactive lipids and radioactive anionic metabolites + glycerol formed during incubation with 16.7 mmol/1 U-[14C]-glucose in the absence or presence of RHC 80 267.
Addition of RHC 80267 (35 ~tmol/1) to the assay medium increased the production of radioactive lipids 4-fold, leading to a conversion of 2.9 + a.9 pmol glucose-islet-2 h (mean + SEM, n = 5) to lipids. However, this increase in lipid production only accounts for about 5% of the increase in glucose utilisation seen in the presence of RHC 80 267.
During 2 h of incubation with 16.7 mmol/1 glucose, 6.5 + 1.1 pmol glucose/islet (mean___ SEM, n = 4) was converted to anionic intermediates + glycerol. This is 5-fold higher than seen in the presence of 3.3 mmol/1 glucose. Addition of 35 ~tmol/1 RHC 80267 at high glucose concentration decreased the radioactivity found in anionic intermediates + glycerol slightly, corresponding to a conversion of 5.a ___ a.2 pmol glucose/islet (mean+ SEM, n = 4). Due to the small differences, an attempt to separate the different radioactive anions was not made.
Glycogen synthesis
It is not known whether glycogen synthesis from glucose in islets proceeds via glucose 6-phosphate and glucose a-phosphate directly or via an indirect pathway in-volving triosephosphates as may be the case in the liver [18] . If the latter is true, different radioactivity incorporation into glycogen would be expected when glycogen synthesis is measured with 3H-glucose and 14C-glucose as substrate.
In 
RHC 80 267 effects on other islet parameters
It was not possible to detect any effect of 35-70 ~tmol/1 RHC 80267 on the activity of adenylate cyclase or phosphoinositide specific phospholipase C, when these enzymes were measured in an islet homogenate. 17.5-35 ~tmol/1 RHC 80267 did not affect the activity of phospholipase A2; whereas higher concentrations of the drug inhibited the activity of phospholipase A2 approx. 25%.
Discussion
RHC 80267 was originally described by Sutherland and Amin [9] as a potent inhibitor of diacylglycerol lipase in enzyme-rich supernatants prepared from canine platelets. Since then this inhibitory effect of the drug has been confirmed in other tissues [19, 20] although some authors have been unable to demonstrate any effects [21, 22] . The drug is described as being able to enter cells [9] and thus seems an appropriate tool to study the effects of interference with intracellular diacylglycerol metabolism on secretion. RHC 80 267 seems to be relatively non-toxic, since the viability of rat pituitary tumor cells has been shown to be unaffected over 4 h of incubation [23] . In concentrations less than approximately 100 l.tmol/1, the drug seems to be rather specific; whereas higher concentrations affect several enzymes involved in leukotrien-and prostacyclin synthesis (unpublished observations).
In concentrations from 10-100 ~tmol/1, the drug has been shown to inhibit prolactin release [23] , to inhibit thyrotropin-stimulated prostaglandin release from rat 115 thyroid lobes [19] and to inhibit carbacholine-induced amylase secretion from guinea pig pancreatic minilobules [24] . In the present experiments with mouse pancreatic islets, 35 ~mol/1 RHC 80267 was shown to inhibit glucose-induced insulin secretion 45%; whereas no effect could be demonstrated on carbachol-induced insulin secretion.
As demonstrated in other tissues [20] , inhibition of diacylglycerol lipase supposedly results in an increased concentration of diacylglycerol and a reduced formation of monoacylglycerol and fatty acids, especially interesting arachidonic acid. Increased concentration of diacylglycerol would be expected to stimulate insulin secretion due to activation of protein kinase C [3] [4] [5] . Reduced formation of arachidonic acid might lead to an inhibition of insufin release as was actually found in the present experiments, since arachidonic acid, either in itself or through metabolism via the lipoxygenase pathway, is supposed to potentiate insulin secretion [7, 8] .
The finding that 70 ~tmol/1 RHC 80267 inhibits both diacylglycerol lipase and glucose-induced insulin secretion almost 100% suggest that arachidonic acid production from diacylglycerol is normally involved in insulin secretion. In comparison, the observation that RHC 80 267 does not inhibit carbachol-enhanced secretion is intriguing. It must, however, be taken into consideration that arachidonic acid may also be liberated by a phospholipase A2 reaction, and that phospholipase A2 may be activated by an increase in diacylglycerol [25, 26] . The relative importance of proteinkinase C, phospholipase A2 and diacylglycerol lipase in glucoseinduced and carbachol-induced insulin secretion is not known, but diacylglycerol activation of protein kinase C and phospholipase A2 may counteract the possible inhibition by RHC 80267 of carbachol-induced secretion. Specific inhibitors of these two enzymes in islets have so far not been demonstrated, but it is possible that a selective inhibition of these enzymes would unmask a more major inhibitory effect of RHC 80 267 on carbachol-induced secretion.
It is interesting that a 3-4 fold increase in glucose utilisation, measured as formation of tritiated water from 5-[3H]-glucose, which to our knowledge always has been found to be positively correlated with insulin secretion, is not able to counteract the effect of a reduced production of arachidonic acid on insulin secretion.
The reason for the increase in glucose utilisation in the presence of RHC 80 267 is not obvious. Our finding that also the cyclooxygenase inhibitor indomethacin increases glucose utilisation and the observation that prostaglandin E2 inhibits glucose-stimulated insulin secretion [27] may indicate the existence of a feed-back regulatory mechanism between arachidonic acid metabolism and glucose utilisation, which, furthermore, may be specific for secretory tissues, as the effect of RHC 80267 on glucose utilisation is not seen in non-secretory tissues as leucocytes and hepatocytes.
A considerable stimulatory effect of cGMP on glucose utilisation has previously been shown in pancreatic rat islets [28] , and in the presence of IBMX, the ester phorbol 12,13-dibutyrate has been shown to reverse the inhibitory action of the (zz-adrenoceptor agonist clonidine upon islet glucose utilisation [29] . The latter effect was ascribed to a protein kinase C mediated activation of guanylate cyclase, but other protein kinase C mediated effects on glucose utilisation cannot be excluded.
In guinea pig pancreatic minilobules, RHC 80 267 has been shown to inhibit production of cyclic GMP [24] , and it thus seems rather unlikely that the increase in glucose utilisation observed in the present experiment is due to cyclic GMP. However, since the concentration of diacylglycerol is assumed to be elevated in the presence of RHC 80 267, other protein kinase C mediated effects on glucose utilisation cannot be excluded in this study either. It should, however, be stressed that phorbolesters do not activate glucose utilisation in the uninhibited basal state [4, 29] .
Unfortunately, our results are obscured by the unexpected finding that glucose utilisation measured as formation of tritiated water from 5-[3H]-glucose in the presence of RHC 80267 is not correlated with either production of 14CO2 from U-[14C]-glucose or lactate production. It thus seems, that RHC 80 267 may interfere with glucose metabolism at more than one stage, at the same time accelerating the pre-pyruvate part of metabolism and not affecting the mitochondrial metabolic events. The latter finding may signal an unchanged ATP-demand in the cells. It is interesting that a similar disproportionate effect on glucose utilisation and glucose oxidation is seen both in parotid cells and in RINm5F cells upon raising the glucose concentration [30, 311. In an attempt to determine which pathway is responsible for the increased production of tritiated water, we have investigated the effect of RHC 80 267 on formation of lipids, glycerol and anionic intermediates derived from glucose. We have also looked for RHC-effects on glycogen synthesis, as this pathway might be co-measured during certain conditions. However, although RHC 80 267 does increase lipid formation from glucose 4-fold, this effect is far too small to explain the observed effect of RHC 80 267 on glucose utilisation. The mechanism of the latter effect thus remains to be determined.
Although a reduced production of arachidonic acid seems to be the most obvious explanation for the observed inhibition of insulin secretion, other explanations are possible. Thus in pituitary tumor cells, RHC 80 267 has been found to inhibit 45calcium entry through the voltage-dependent calcium channels [23] , and diacylglycerol-stimulated protein kinase C has been shown to activate I173 phosphomonoesterase [32] . A similar effect in pancreatic islets would be expected to result in inhibition of glucose-induced insulin secretion [33] . One of the aims of the present study was to evaluate if potentiation of insulin secretion is regulated by an increase in the intracellular concentration of diacylglycerol. In doing this, we have attempted to raise the concentration of diacylglycerol by addition of RHC 80 267. As discussed above, it seems, however, that a possible positive effect of diacylglycerol is obscured by other effects of the diacylglycerol lipase inhibitor.
Demonstration of a diacylglycerol activation of insulin secretion might also be complicated by the transient nature of the increase in diacylglycerol, which has been demonstrated in islets [34] as well as in other tissues [35] and which may even persist in the presence of RHC 80 267 due to a rapid conversion of diacylglycerol to phosphatidic acid.
To overcome this problem, we have also measured insulin secretion in the presence of R 59 022, which has been shown to inhibit diacylglycerol kinase in human red blood cells [36] . Addition of this agent in combination with RHC 80267 resulted in a complete reversal of the inhibition seen in the presence of RHC 80 267 alone and may thus indicate that an increase in endogenous diacylglycerol does stimulate insulin secretion, although it remains to be determined if the increase in the concentration of diacylglycerol established by secretagogues in the absence of inlhibitors of diacylglycerol metabolism is sufficient to activate protein kinase C in the islets.
In conclusion, our results support the suggestion [6] that arachidonic acid production from diacylglycerol is normally involved in the regulation of insulin secretion, and they indicate that endogenously produced diacylglycerol may indeed affect insulin secretion. The results, furthermore, have shown that increased glucose utilisation, as measured by formation of tritiated water from 5-[3H]-glucose, is not necessarily associated with enhanced insulin secretion.
